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Escherichia coli is the most common organism associated with asymptomatic bacteriuria (ABU). In contrast
to uropathogenic E. coli (UPEC), which causes symptomatic urinary tract infections (UTI), very little is known
about the mechanisms by which these strains colonize the human urinary tract. The prototype ABU E. coli
strain 83972 was originally isolated from a girl who had carried it asymptomatically for 3 years. Deliberate
colonization of UTI-susceptible individuals with E. coli 83972 has been used successfully as an alternative
approach for the treatment of patients who are refractory to conventional therapy. Colonization with strain
83972 appears to prevent infection with UPEC strains in such patients despite the fact that this strain is unable
to express the primary adhesins involved in UTI, viz. P and type 1 fimbriae. Here we investigated the growth
characteristics of E. coli 83972 in human urine and show that it can outcompete a representative spectrum of
UPEC strains for growth in urine. The unique ability of ABU E. coli 83972 to outcompete UPEC in urine was
also demonstrated in a murine model of human UTI, confirming the selective advantage over UPEC in vivo.
Comparison of global gene expression profiles of E. coli 83972 grown in lab medium and human urine revealed
significant differences in expression levels in the two media; significant down-regulation of genes encoding
virulence factors such as hemolysin, lipid A, and capsular polysaccharides was observed in cells grown in urine.
Clearly, divergent abilities of ABU E. coli and UPEC to exploit human urine as a niche for persistence and
survival suggest that these key differences may be exploited for preventative and/or therapeutic approaches.
Urinary tract infection (UTI) is a serious health problem
affecting millions of people each year. It is estimated that there
are more than 10 million cases in Western Europe alone per
year. The recurrence rate is high, and often the infections tend
to become chronic with many episodes. UTI usually starts as a
bladder infection but often evolves to encompass the kidneys
and ultimately can result in renal failure or dissemination to
the blood. UTI is the most common infection in patients with
a chronic indwelling bladder catheter; bacteriuria is essentially
unavoidable in this patient group (9). UTI is classified into
disease categories according to the site of infection: cystitis
(the bladder), pyelonephritis (the kidney), and bacteriuria (the
urine). Colonization of urine in the absence of clinical symp-
toms is called asymptomatic bacteriuria (ABU). ABU occurs in
up to 6% of healthy individuals and 20% of elderly individuals.
ABU strains generally do not cause symptoms, and most pa-
tients with ABU do not need treatment. Furthermore, colo-
nizing ABU strains may actually help to prevent infection by
other more virulent bacteria (8, 14, 44, 45).
Escherichia coli is responsible for more than 80% of all UTIs
and causes both ABU and symptomatic UTI (13, 39). These
infections are typically caused by a single bacterial clone and
are in effect monocultures. The ability of uropathogenic E. coli
(UPEC) to cause symptomatic UTI is associated with the ex-
pression of a variety of virulence factors, including adhesins
(e.g., type 1 and P fimbriae) and toxins (e.g., hemolysin) (20,
33). Bacterial adherence is generally considered to be a pivotal
step in the colonization of host tissue surfaces submitted to
hydrodynamic flow forces. The human urinary tract is submit-
ted to brutal hydrodynamic shear forces, and adherence to the
urinary tract epithelium enables bacteria to resist removal by
urine flow. Bacterial adherence not only contributes to colo-
nization, but also to invasion, biofilm formation, and host cell
damage. The two primary fimbrial adhesins associated with
UPEC strains are type 1 and P fimbriae. Type 1 fimbriae are
mainly associated with cystitis and confer binding to -D-man-
nosylated proteins, such as uroplakins, which are abundant in
the bladder (7, 46). Expression of P fimbriae is primarily linked
to pyelonephritic strains. P fimbriae recognize the -D-galac-
topyranosyl-(1-4)--D-galactopyranoside moiety present in the
globoseries of glycolipids located in the human kidney as well
as on erythrocytes (21). Both type 1 and P fimbriae trigger host
responses that include cytokine production, inflammation, and
exfoliation of infected bladder epithelial cells (31, 36, 48).
E. coli strain 83972 is a clinical isolate capable of long-term
bladder colonization. The strain was originally isolated from a
young Swedish girl with ABU who had carried it for at least 3
years without symptoms (1, 25). It is well adapted for growth in
the human urinary tract, where it establishes long-term bacte-
riuria (1, 14, 47, 49). The strain has been used for prophylactic
purposes; as such, it has been used as an alternative treatment
in patients with recurrent UTI who are refractory to conven-
tional therapy (8, 14). Here the bladders of patients are delib-
erately colonized with E. coli 83972 in order to prevent disease-
causing strains from colonizing. Deliberate colonization with
E. coli 83972 has for example been shown to reduce the fre-
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quency of UTI in patients with spinal cord injury and neuro-
genic bladder (49), and the strain can prevent catheter coloni-
zation by bacterial and fungal uropathogens (8, 44, 45). In
effect, extensive trials have shown that infection with poten-
tially dangerous UPEC strains often does not take place in
such patients as long as the ABU strain stays in the bladder.
The mechanism of bladder colonization by E. coli 83972 is not
known. Also, the mechanisms underlying its ability to keep
other strains away are not known either. Recently, we found
that E. coli 83972 is unable to express functional type 1 and P
fimbriae (19). The results explained to a large degree why the
strain does not cause symptoms in the host. However, impor-
tant outstanding questions remain, namely, (i) how is the strain
capable of efficient bladder colonization and (ii) how does the
strain keep pathogenic E. coli from infecting the bladder. In
this study we approach these questions.
MATERIALS AND METHODS
Bacterial strains. The strains used in this study are described in Table 1. E. coli
83972 (OR:K5:H) was originally isolated from a young Swedish girl (1, 25). E.
coli 83972 is a prototype ABU strain and lacks defined O and K surface antigens.
It carries adhesin gene clusters homologous to fim, pap, uca, and foc but does not
express functional fimbrial adhesins after in vitro culture or when recovered from the
urinary tract (1, 15). The E. coli strains 536, CFT073, NU14, and 1177 are all
well-characterized uropathogenic strains isolated from patients with severe urinary
tract infections (Table 1). Strains 536 and NU14 are naturally resistant to strepto-
mycin. These phenotypes were used to monitor the population composition in
growth competition experiments. In the cases of strains CFT073 and 1177, kanamy-
cin-resistant tagged versions were constructed. The CFT073 fim::kan mutant was
constructed by using the Red recombinase gene replacement system. Briefly, the
kanamycin gene from plasmid pKD4 was amplified by primers containing 50-nucle-
otide fim homology extensions (286, 5-GTCGATTGAGGATTTCGGATATTGA
TCTTAAGGCAAAGTGGTGTAGGCTGGAGCTGCTTC; 287, 5-GCTCCTA
ACGATACCGTGTTATTCGCTGGAATAATCGTACCATATGAATATCCT
CCTTAG). This product was digested with DpnI and transformed into
CFT073(pKD46), and kanamycin-resistant colonies were selected. The correct
double-crossover and recombination event was confirmed by PCR and Southern
blotting. The Red helper plasmid pKD46 was cured by growth at 37°C, and the
subsequent strain was designated PK1097. The 1177 fim::kan mutant (PK625)
was constructed using the temperature-sensitive suicide plasmid as previously
described (37). In short, a kan cassette flanked by DNA segments containing the
upstream and downstream regions of the fim gene cluster, respectively, was used
for homologous double-crossover recombination. Competition experiments be-
tween the kanamycin-resistant strains and their natural/nonresistant counter-
parts were performed to confirm that addition of the resistance gene had not
altered the growth behaviors of the strains.
Growth conditions for growth characteristics and competition experiments.
For each growth experiment, strains were grown in monocultures or in mixed
cultures in LB or human urine collected from at least three healthy men and
women volunteers who had no history of UTI or antibiotic use in the prior 2
months. The urine was pooled, filter sterilized, stored at 4°C, and used within the
next 1 to 3 days. For measuring growth characteristics, monocultures were grown
in 20 ml urine inoculated with an overnight urine culture to an optical density at
600 nm (OD600) of 0.05 and grown in a water bath incubator at 37°C and 130
rpm. The OD600 was measured every 30 min until cells reached stationary phase.
Each experiment was performed in triplicate and repeated at least twice.
For competition experiments, mixed cultures were grown in 20 ml urine inoc-
ulated 1:1 with freshly grown precultures of E. coli 83972 and either 536,
CFT073, NU14, or 1177 to an OD600 of 0.05. Samples from each culture were
extracted at the start of the cultivation, diluted, and plated on LB plates with and
without antibiotic to confirm the 1:1 ratio between E. coli 83972 and the UPEC
strain in question. The cultures were grown at 37°C and 130 rpm, and samples
were extracted after 17 h, diluted, and plated on both LB plates and LB plates
complemented with the appropriate antibiotic. Each competition experiment was
performed in duplicate or triplicate and repeated at least twice. To investigate
growth competition in more detail, 83972 and NU14 were inoculated 1:1 to an
OD600 of 0.05, in duplicate, and grown as described above, and samples were
extracted every hour for measurement of the OD and viable counts.
To monitor the role of the starting ratio of the strains, E. coli 83972 and NU14
cultures were mixed 1:20 in 20 ml urine to an OD600 of 0.05. The starting ratio
was confirmed by plating as described above; NU14 constituted 95% (0.95 
0.02, mean  standard deviation) of the cultivation at the starting point. The
cultures were grown and analyzed as described above.
In the case of strains CFT073 and 1177, competition experiments between the
kanamycin-resistant versions and their natural/nonresistant counterparts were
performed as described above. The competitions resulted in equal amounts of
each strain.
Growth conditions and stabilization of RNA for microarray experiments.
Human urine was collected from four healthy men and women volunteers who
had no history of UTI or antibiotic use in the prior 2 months. The urine was
pooled, filter sterilized, stored at 4°C, and used the following day. Overnight
cultures of E. coli 83972 were grown in pooled human urine or morpholinepro-
panesulfonic acid (MOPS) minimal medium supplemented with 0.2% glucose
until reaching exponential phase and then used for inoculation of 50 ml urine or
MOPS to an OD600 of 0.05. The cultures were grown at 37°C and 130 rpm, and
5-ml samples for isolation of RNA were extracted from three individual cultures
at mid-exponential phase (corresponding to an OD600 of approximately 0.4 and
0.5 in urine and MOPS, respectively). Extracted samples were immediately
mixed with two volumes of RNAprotect bacteria reagent (QIAGEN AG, Basel,
Switzerland), incubated for 5 min at room temperature to stabilize RNA, and
centrifuged. The pellets were then stored at 80°C.
RNA isolation and cDNA labeling. Total RNA was isolated using the RNeasy
Mini kit (QIAGEN AG). Eluted RNA samples were treated with DNase I and
repurified using RNeasy Mini columns. The quality of the total RNA was exam-
ined by agarose gel electrophoresis and by measuring the absorbance at 260 and
280 nm. Purified RNA was precipitated with ethanol and stored at 80°C until
further use. Conversion of RNA to cDNA and microarray analysis were per-
formed according to GeneChip Expression Analysis technical manual 701023,
rev. 4 (Affymetrix, Inc., Santa Clara, CA). Briefly, 10 g of RNA was mixed with
750 ng of random hexamer primers (Invitrogen), denatured at 70°C for 10 min,
and then allowed to anneal, and cDNA synthesis was performed using Super-
Script II reverse transcriptase (Invitrogen). cDNA was purified using a MinElute
PCR purification kit (QIAGEN) and fragmented with DNase I. DNase I was
inactivated by heating at 98°C for 10 min, and the 3 terminus of fragmented
cDNA was labeled using the GeneChip DNA labeling reagent (Affymetrix).
DNA microarray hybridization. GeneChip E. coli Genome 2.0 arrays (Af-
fymetrix) were used for hybridization of the labeled cDNA. In total, six samples
were hybridized to GeneChip E. coli Genome 2.0 arrays; three chips were
hybridized with samples from E. coli 83972 grown in MOPS in triplicate, and
three chips were hybridized with cells grown in pooled human urine in three
individual flasks. Hybridization, washing, and staining were performed according
to GeneChip Expression Analysis technical manual 701023, rev. 4 (Affymetrix),
and the microarrays were scanned using the GeneChip Scanner 3000. The Ge-
neChip E. coli genome array contains probe sets to detect transcripts from the
K-12 strain of E. coli and three pathogenic strains of E. coli. The GeneChip E.
coli Genome 2.0 array includes approximately 10,000 probe sets for all 20,366
genes present in the K-12 (MG1655), CFT073 (uropathogenic), O157:H7-
EDL933 (enteropathogenic), and O157:H7-Sakai (enteropathogenic) strains.
Due to the high degree of similarity between the E. coli strains, whenever
possible a single probe set is tiled to represent the equivalent ortholog in all four
strains.
Data analysis. Array normalization and expression value calculations were
performed using the DNA-Chip Analyzer (dChip) 1.3 software program (http:
//www.dchip.org/) (23). The invariant set normalization method (24) was used to
normalize arrays at probe cell level to make them comparable, and the model-
based (perfect match/mismatch) method was used for probe selection and com-
TABLE 1. Strains used in this study
E. coli
strain Relevant characteristics Reference
83972 ABU isolate (OR:K5:H) 1
MG1655 K-12 reference strain 3
536 UPEC isolate (O6:K15:H31), Smr 4
CFT073 UPEC isolate (O6:K2:H1) 30
PK1097 CFT073, fim::kan This study
NU14 UPEC isolate (O18:K1:H7), Smr 16
1177 UPEC isolate (O1:K1:H7) 28
PK625 1177, fim::kan This study
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puting expression values. These expression levels were attached with standard
errors as measurement accuracy, which were subsequently used to compute 90%
confidence intervals of changes in a two-group comparison. The three arrays
hybridized with samples from E. coli 83972 grown in MOPS were used as the
baseline for calculation of changes on the three arrays hybridized with samples
from E. coli 83972 grown in urine. In total, 2,633 genes (26%) were filtered as
significantly changed in urine compared with MOPS; 1,422 and 850 of these
genes were specific for MG1655 and CFT073, respectively.
In dChip, estimation of the percentages of genes identified by chance, the
empirical false discovery rate (FDR), can be performed by permutation. Per-
muting our samples randomly 1,000 times, using the same comparison criteria as
when comparing urine- with MOPS-grown samples, resulted in an FDR of 0.3%,
or seven false-positive genes.
RT-PCR. Reverse transcription-PCR (RT-PCR) was performed to confirm
DNA microarray gene expression data. Total RNA was isolated exactly as de-
scribed above and treated with DNase I to remove any traces of DNA. RNA was
converted to cDNA using SuperScript II (Invitrogen Life Technologies). cDNA
was used directly as template for PCR, and a negative control on the RNA
sample (not converted to cDNA) was run in parallel to confirm that all DNA had
been removed in the earlier step. The total number of cycles used in PCR ranged
from 12 to 30. RT-PCR products were examined by agarose gel electrophoresis.
The following primers were used in RT-PCR and PCR: papA, 620 (5-GTGAA
GTTTGATGGGGCGACC) and 621 (5-CGCAACTGCTGAGAAAGCACC);
16S, 622 (5-CGGATTGGAGTCTGCAACTCG) and 623 (5-CACAAAGTGG
TAAGCGCCCTC).
Murine model of UTI. A modification of the murine model of UTI was used
for this study (12). Female CBA mice (8 to 10 weeks) were purchased from the
Animal Resources Center, Western Australia, and housed in sterile cages with ad
libitum access to sterile water. Urine was collected from each mouse 24 h prior
to challenge and examined microscopically with a hemocytometer and by culture.
Mice with a combination of 	5 
 102 CFU of bacteria per ml of urine and 	2

 105 white blood cells in urine were defined as having a preexisting condition
and were excluded from the study. Mice (n  7) were anesthetized by brief
inhalation exposure to isoflurane, and the periurethral area was sterilized by
swabbing with 10% povidone-iodine solution, which was removed with sterile
water. Mice were catheterized using a sterile Teflon catheter (0.28-mm internal
diameter, 0.61-mm outer diameter, and 25-mm length; Terumo) by inserting the
device directly into the bladder through the urethra. An inoculum of 25 l,
containing 109 CFU of bacteria in phosphate-buffered saline containing 0.1%
India ink (for visualization of inocula at autopsy), was instilled directly into the
bladder using a 1-ml tuberculin syringe attached to the catheter. The catheter
was removed immediately after the challenge, and mice were returned to their
cages. Urine was collected from each mouse at 24 h after inoculation for quan-
titative colony counts.
RESULTS
Growth characteristics of E. coli 83972. In an attempt to
understand the bladder colonization properties of E. coli strain
83972 better, we initially focused on its growth characteristics
in human urine. Under normal conditions, an adult human
being produces 1 to 2 liters of urine per day, all of which pass
through the bladder. Arguably, the ability to grow in human
urine must be an important criterion for colonization of the
bladder. The strain grows well in human urine in vitro and,
depending on the individual batch of urine used, grows expo-
nentially, with doubling times ranging from 45 min to 60 min,
and it levels out in stationary phase with an OD600 of 0.5 to 0.9.
The E. coli K-12 reference strain MG1655 is unable to grow in
urine and cannot be used for comparison. However, in LB
medium strain 83972 shows slightly better growth characteris-
tics than the K-12 strain (data not shown). For comparison, we
probed the growth characteristics of some well-characterized
UPEC strains, viz. E. coli strains 536, CFT073, NU14, and
1177, all isolated from severe cases of urinary tract infections
(Table 1). Surprisingly, all four UPEC strains performed sig-
nificantly poorer than strain 83972 when grown in urine, with
doubling times in the exponential phase 10 to 100% longer
(two-sample two-tailed t test, P  0.002), and they entered
stationary phase at an OD600 10 to 30% lower than that of
83972 (P  0.04) (Fig. 1). Accordingly, due to its faster dou-
bling time and higher carrying capacity in urine, it is highly
likely that strain 83972 should be able to outcompete these
UPEC strains within a relatively modest number of genera-
tions.
E. coli 83972 competition with UPEC strains in human
urine. In order to monitor if the superior growth characteris-
tics of strain 83972 were a general phenomenon, we competed
it against our panel of well-characterized UPEC strains (Table
1). This was done by incubation of sterile human urine with
equal amounts of strain 83972 and the UPEC strain in question
FIG. 1. (A) Growth of ABU E. coli 83972 and UPEC strains 536, CFT073, NU14, and 1177 in human urine. The curves are shown as means
of triplicates, and error bars indicate standard deviations (n1). (B) The doubling time during exponential phase for each strain was calculated
and is shown as the mean of triplicates. Bars indicate standard deviations. (C) Competition experiment between 83972 and NU14 mixed 1:1 at the
starting point in human urine. Values are means of duplicates, and error bars indicate standard deviations.
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and then monitoring the percentage of each strain after over-
night cultivation by selective plating. In all cases, strain 83972
outcompeted the UPEC strain; even though the UPEC strain
constituted 50% of the population at the start of the cultiva-
tion, it ended up constituting only 3% to 4% in the case of
CFT073, NU14, and 1177 and 29% in the case of strain 536
(paired two-tailed t test, P  0.001) (Fig. 2). Figure 1C, dis-
playing the competition between 83972 and NU14 during the
first 7 hours, reveals that E. coli 83972 constitutes about 80%
of the population already after 2 h. To further investigate the
degree of advantage by E. coli 83972, it was competed against
NU14 with a starting ratio of 1 to 20; although NU14 consti-
tuted 95% of the population at the start of the experiment, it
accounted for only 7% of the population after 17 h (paired
two-tailed t test, P  0.01). Taken together the data show that
strain 83972 is able to outgrow a representative spectrum of
UPEC strains.
Global gene expression of E. coli 83972 in human urine. The
genomic expression profile of E. coli 83972 grown in pooled,
filtered human urine was compared with the strain grown in
MOPS-glucose medium. Samples were extracted during mid-
exponential growth phase in order to best mimic the situation
the cells encounter in the human bladder; in the bladder any
colonizing organism will continuously be provided with fresh
growth medium (i.e., urine), which most likely will keep the
cells in growth phase and prevent them from reaching station-
ary phase. RNA isolated from exponentially growing cultures
(in triplicate) was used for hybridization of microarrays, and
the data were analyzed as described in Materials and Methods.
For analysis, the GeneChip E. coli Genome 2.0 array was
employed. This microarray contains 10,000 probe sets for all
20,366 genes present in E. coli strains MG1655, CFT073,
EDL933, and O157:H7-Sakai.
The analysis of the microarray data is described in Materials
and Methods. Whether a fold change in expression of a gene
observed between two different arrays could be considered
significant or not was not solely dependent on the magnitude of
the change, but also on the absolute signal on the two arrays.
A large up-regulation of a gene has to have a signal that is
present on the sample array, but not on the baseline array,
while in the case of a small up-regulation (low fold change,
closer to 1.0), the signal has to be present and high on both the
sample and the baseline array, and vice versa for down-regu-
lated genes. Therefore, in our analysis we have only considered
an up- or down-regulation to be significant if it meets these
criteria, i.e., for a low fold change (1.4 to 1.9) to be considered
significant the signal has to be present and high on all three
baseline arrays as well as the three sample arrays. Moreover,
the comparison criteria were carefully chosen to make sure
that the empirical FDR was kept low (0.3%, i.e., seven false-
positive genes). The estimation of FDR has become widely
accepted as appropriate (10) and, furthermore, it has been
argued that FDR is a more natural scale to work on rather than
the P value (34).
Overall, 626 genes (10%) were expressed at significantly
higher levels in human urine and 1,646 genes (25%) were
significantly down-regulated during growth in urine, whereof
383 and 1,039 genes, respectively, were MG1655 transcripts
and the remaining genes were CFT073 (uropathogenic) tran-
scripts. Classification of the MG1655 genes into functional
groups (41, 42) revealed that a large number of the genes
involved in carbohydrate transport and metabolism, energy
production and conversion, and inorganic ion transport and
metabolism were significantly up-regulated in urine (Table 2).
Some of the genes belonging to these groups can also be found
among the genes displaying the highest fold changes in urine
compared with minimal medium, particularly genes encoding
proteins involved in iron transport and metabolism (Table 3).
Iron acquisition genes. The concentration of soluble forms
of iron is very low in the urinary tract and is a growth-limiting
factor for bacteria. Consequently, iron acquisition plays an
important role in bacterial survival and pathogenicity. In strain
83972 many genes involved in iron uptake and transport were
significantly up-regulated in human urine (Fig. 3A). Transcrip-
tion from genes encoding proteins involved in enterobactin
synthesis, entBCDEF, were up-regulated 20- to 44-fold, and the
gene encoding the highly specific ferric enterobactin receptor,
fepA, revealed one of the highest signals and was up-regulated
51-fold. Genes encoding FhuA, FhuE, and IutA, which trans-
port hydroxamate siderophores, were induced 13-, 12-, and
38-fold, and genes encoding Fiu and Cir, which transport cat-
echolate siderophores, were induced 17- and 21-fold. The
transport of iron across the outer membrane is dependent
upon the energy-transducing TonB-ExbB-ExbD complex;
these genes were up-regulated between 12- and 18-fold in
urine.
Genes encoding proteins responsible for iron uptake with-
out siderophores, sitABCD, were significantly up-regulated
(17- to 47-fold); sitB showed the 10th highest signal in urine. It
has been demonstrated that the sit cluster is required for full
virulence of Salmonella enterica serovar Typhimurium (17).
Other virulence-associated genes, iutA and iucABCD, respon-
sible for aerobactin uptake and synthesis, were up-regulated
29- to 48-fold in urine. The iroN gene, encoding a siderophore
receptor that contributes to urovirulence (35), was highly up-
regulated in urine (37-fold), as were the rest of the genes in the
iro cluster (iroBCDE were induced 6.3- to 76-fold). The genes
encoding the Chu heme transport system, chuASTWXYU, were
up-regulated 5.5- to 46-fold; chuA has been shown to be im-
FIG. 2. Results from growth competition experiments (1:1) be-
tween E. coli 83972 and UPEC strains after 17 h of growth in human
urine. Each value is an average of four individual shake flasks obtained
from two separate experiments in different batches of urine. In all four
competition experiments, strain 83972 was present in significantly
higher numbers than the UPEC isolate (paired two-tailed t test, P 
0.001).
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portant for the virulence of a uropathogenic E. coli strain (43).
The small regulatory antisense RNA (ryhB) involved in iron
homeostasis was up-regulated 38-fold. RyhB down-regulates
the mRNA levels for the genes that are known to be positively
regulated by Fur (ferric uptake regulator) (29). The fur gene
itself showed no change in expression in urine compared with
MOPS. Taken together, the data indicate that strain 83972 has
numerous genes encoding products that are well suited to cope
with an iron-poor environment and that these are highly ex-
pressed during growth in urine.
Carbohydrate transport and metabolism. The ara cluster
belonged to one of the most up-regulated in urine (Table 3).
The genes araABD, which are responsible for the conversion of
arabinose to xylulose-5-phosphate, were up-regulated 32-, 46-,
and 46-fold, respectively. The genes encoding arabinose trans-
porters, both the arabinose/proton symporter gene araE and
TABLE 2. Up- and down-regulated MG1655 genes in each functional group of E. coli 83972 grown in urine versus MOPS
Functional group
No. (%) of genes up- or down-regulated,
urine vs MOPS Total no.
of genes
Up in urine Down in urine
Amino acid transport and metabolism 39 (13) 81 (27) 296
Carbohydrate transport and metabolism 64 (21) 56 (19) 298
Cell cycle control, mitosis, and meiosis 0 (0) 14 (45) 31
Cell motility 1 (1) 9 (10) 91
Cell wall/membrane biogenesis 9 (5) 78 (39) 200
Coenzyme transport and metabolism 4 (4) 43 (40) 108
Defense mechanisms 1 (3) 12 (34) 35
Energy production and conversion 38 (16) 55 (23) 240
Function unknown 28 (11) 83 (34) 247
General function prediction only 22 (8) 78 (29) 269
Inorganic ion transport and metabolism 26 (16) 39 (24) 160
Intracellular trafficking and secretion 2 (6) 17 (47) 36
Lipid transport and metabolism 5 (7) 22 (31) 71
Nucleotide transport and metabolism 10 (13) 33 (42) 78
Posttranslational modification, protein turnover, chaperones 13 (11) 39 (33) 119
Replication, recombination, and repair 3 (2) 46 (28) 165
Secondary metabolite biosynthesis, transport, and catabolism 9 (17) 9 (17) 54
Signal transduction mechanisms 11 (9) 31 (27) 116
Transcription 15 (6) 54 (23) 235
Translation 4 (3) 49 (31) 156
Not in COGs 79 (7) 191 (18) 1,065
Total protein-coding genes 383 (9) 1039 (26) 4,070
TABLE 3. Top 25 up-regulated MG1655 and CFT073 genes in E. coli 83972 grown in urine compared with minimal lab medium
Gene b/c code Function Signal Fold change
c1596 c1596 Hypothetical protein 2,088 103.5
iroB c1254 Putative glucosyltransferase 4,953 76.4
fepA c0669 Ferric enterobactin receptor precursor 4,538 74.8
yeiC c2701 Hypothetical sugar kinase yeiC 4,443 55.8
yeiN b2165 Hypothetical protein 1,151 55.2
fepA b0584 Outer membrane receptor for ferric enterobactin and colicins B and D 5,347 50.8
iucA c3627 IucA protein 2,421 48.2
ycdO b1018 Hypothetical protein 3,077 46.8
sitA c1600 SitA protein 4,722 46.7
chuX c4315 Hypothetical protein 2,400 46.0
araD b0061 L-Ribulose-5-phosphate 4-epimerase 2,969 45.8
araB b0063 L-Ribulokinase 3,571 45.6
iucD c3624 lucD protein 4,015 45.2
b1498 b1498 Putative sulfatase 2,883 44.5
entC b0593 Isochorismate synthase, enterobactin biosynthesis 2,848 44.4
uidB b1616 Glucuronide permease 2,379 44.2
b2737 b2737 Hypothetical protein 4,792 42.7
sitB c1599 SitB protein 5,082 41.3
araE b2841 Low-affinity L-arabinose transport system, proton symport protein 2,921 40.0
b2736 b2736 Putative dehydrogenase 4,616 38.6
iutA c3623 IutA protein 3,446 38.4
ryhB b4451 Regulatory RNA-mediating Fur regulon 4,481 38.3
iroN c1250 Siderophore receptor IroN 4,640 37.2
srlB b2704 PTS family enzyme IIA, glucitol/sorbitol specific 1,643 33.8
c4310 c4310 Hypothetical protein 4,530 32.1
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the ABC transporter encoding genes araFGH, were up-regu-
lated (40-, 14-, 17-, and 25-fold, respectively).
The degradation of sugar acids was highly up-regulated in
urine. All the genes involved in the degradation pathways of
galacturonate, glucuronate, and galactonate were significantly
up-regulated up to 77-fold, and the genes encoding transport-
ers of these compounds were up-regulated up to 44-fold (Fig.
4). The fructuronic acid transporter-encoding gene, gntP,
which is divergently transcribed from uxuAB, was up-regulated
4.2-fold. The gene encoding N-acetylneuraminate lyase, nanA,
which catalyzes the breakdown of sialic acid, was up-regulated
19-fold. Furthermore, many genes involved in the transport of
carbohydrates were up-regulated in urine compared with min-
imal medium; genes encoding proteins responsible for trans-
port of sorbitol (srlAB), galactose (mglABC), maltose (lamB),
xylose (xylFGH), and mannose/fructose (manXYZ) were all
significantly up-regulated 2.4- to 34-fold.
Adhesins. E. coli 83972 harbors a nonfunctional pap gene
cluster, encoding P fimbriae, and a truncated fim gene cluster,
encoding type 1 fimbriae (19). Our microarray data revealed
that half of the pap genes were significantly up-regulated in
urine: papHDJF were up-regulated 2- to 5-fold, and the gene
encoding the major subunit, papA, was up-regulated 19-fold
(Fig. 3B). While the signals for fimEAIC could not be detected
in E. coli 83972 due to a large deletion in the fim cluster, the
remaining fim genes, fimBDFGH, displayed low signals and
were all down-regulated in urine.
The foc/sfa cluster encoding F1C fimbriae was partly up-
regulated in E. coli 83972, with focA, encoding the major sub-
unit, up-regulated 1.8-fold in human urine. Other fimbrial
genes significantly changed in urine belonged to the recently
characterized auf cluster (6), for which genes were down-reg-
ulated 4.3- to 221-fold. Furthermore, the hypothetical fimbrial-
like protein precursors yadN and ygiL were down-regulated
4.3- and 115-fold, respectively, and two genes encoding puta-
tive adhesins, eaeH and c4424, were down-regulated 12- and
3.8-fold. Expression from the flu gene encoding aggregation
factor Ag43 was very low and showed no significant change
when grown in urine.
Other virulence factors. The pore-forming hemolysin
(HlyA) is considered an important virulence factor in E. coli
extraintestinal infections, such as those of the upper urinary
tract. The genes determining the synthesis, activation, and
transport of hemolysin, hlyCABD, were all down-regulated in
urine (106-, 9.2-, 2.8-, and 90-fold, respectively). This was con-
firmed by lack of hemolysis on blood agar plates (data not
shown). Of the genes encoding proteins involved in biosynthe-
sis of lipopolysaccharides, most were significantly down-regu-
lated in urine, the genes involved in the enterobacterial com-
mon antigen biosynthesis pathway (rffACDGHMT, wecBF, and
FIG. 3. Expression levels of iron acquisition systems (A) and adhesins (B) in E. coli 83972 grown in urine. The numbers indicate fold changes
of expression levels for genes significantly changed in urine compared with MOPS. Asterisks indicate CFT073 transcripts in cases where there are
two genes with the same name.
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rfe) were all down-regulated 2.0- to 6.3-fold, the genes involved
in colonic acid biosynthesis (cpsB, gmd, fcl, and ugd) were
down-regulated 4.0- to 26-fold, and the genes involved in the
synthesis of lipid A (lpxBHKP, kdsABC, htrB, and kdtA) were
down-regulated 1.6- to 6.0-fold. The rcsA gene, encoding a
positive regulator of capsular polysaccharide synthesis, was
down-regulated 16-fold in urine. The genes kpsEDCS, involved
in the transport of polysaccharide to the cell surface, were all
down-regulated 2.5- to 6.5-fold. The rfaH gene is another vir-
ulence-associated gene which displayed very low signals and
significant down-regulation in urine (3.7-fold). RfaH is a global
regulator which modifies expression of several virulence fac-
tors, and disruption of the rfaH gene in uropathogenic E. coli
has been shown to result in a significant decrease in virulence
(32).
Taken together the array data show that E. coli 83972 ex-
presses all known iron transport and uptake systems when
grown in urine; the strain also showed high expression levels of
genes involved in uptake and metabolism of nutrients found in
urine, while most of the genes encoding known virulence fac-
tors were down-regulated in urine. It is obvious that the strat-
egy to keep and express growth-enhancing genes while shutting
off virulence genes that may provoke the host response must be
an optimal approach for successful long-term colonization of
the urinary tract.
Verification of microarray results. RT-PCR was performed
to verify the transcript levels for an example gene, papA. papA
was significantly up-regulated 19-fold in urine and showed very
low signals in MOPS. papA could not be detected in the sam-
ples from MOPS, not even after 30 cycles of PCR, while papA
was detected in all three urine samples, visualized as strong
bands on an agarose gel. 16S was used as a normalizing inter-
nal standard and was detected with the same intensity in all
samples.
The expression levels of the fim genes revealed the sensitiv-
ity of the microarrays. Sequencing of the fim cluster of E. coli
83972 revealed that a large part of the cluster is deleted in the
strain, i.e., a 4.25-kb deletion between fimB and fimD, resulting
in complete absence of fimEAIC, leaving only fimF, fimG, and
fimH unaffected (19). The signal from fimEAIC was very low
and varied between 7 and 53, with an average of 27 and 35 for
MOPS and urine, respectively. The signals of fimBDFGH var-
ied between 136 and 1,209 with an average of 911 and 275 for
MOPS and urine, respectively. The signal levels of the different
fim genes on the arrays correspond well to the actual presence
of fim genes in E. coli 83972.
E. coli 83972 competition with UPEC strain NU14 in mouse
bladder. Our growth studies combined with the global gene
expression data demonstrate that E. coli 83972 is highly
adapted to growth in human urine. Since other studies have
demonstrated a prophylactic effect of this strain in the pres-
ence of other pathogens, we competed 83972 against UPEC
NU14 in the mouse UTI model. Mice were infected with equal
numbers of NU14 (alone) or NU14 and 83972 (in combination,
50% mixed infection of each). After 24 h, the total number of
bacteria in the urine of mice infected with NU14 or an equal
combination of NU14 and 83972 was almost identical (Fig. 5).
However, when examining the percentage of each individual
strain in the mice receiving the mixed combination of strains,
we observed that 83972 was almost totally dominant (98.7%
versus 1.3%; paired two-tailed t test, P  0.001). Thus, 83972
is able to outcompete UPEC in an in vivo UTI infection model
in addition to in vitro growth experiments in human urine.
DISCUSSION
Healthy adult humans normally produce 1 to 2 liters of urine
per day, which must pass through the bladder, corresponding
FIG. 4. Transport and degradation pathways of the sugar acids
galacturonate, glucuronide, and galactonate. The numbers indicate
significant fold changes of expression levels for genes in E. coli 83972
grown in urine compared with the same cells grown in MOPS.
FIG. 5. Results from mice (n  7) challenged for 24 h with the
UPEC isolate NU14 or E. coli 83972 and NU14 (1:1). (A) Mean total
number of CFU per ml of urine  the standard error of the mean;
(B) percentages of NU14 and ABU 83972 calculated from differential
colony counts. Total colony counts were not influenced by the presence
of 83972. E. coli 83972 was present in significantly higher numbers in
urine from mice compared with NU14 (98.7% versus 1.3%; paired
two-tailed t test, P  0.001).
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to average flow rates of 40 to 80 ml per hour. An adult human
bladder has a volume of 200 to 400 ml, and micturition causes
the release of roughly the same volume of urine; the volume of
urine remaining in the bladder following micturition is 1 ml
(38). The contribution of bladder hydrodynamics on the elim-
ination of bacteria has been recognized for several decades (5,
27), and it has been suggested that without adhesin-assisted
attachment to the bladder surface, E. coli would not be able to
overcome the losses caused by micturition and, therefore, it
would be unable to establish in the urinary tract (2, 40). Im-
plicit in this suggestion is the notion that the growth rate of E.
coli in urine is too slow to cope with the losses incurred by
micturition. Meanwhile, mathematical modeling suggests that
if the growth rate of a strain is high enough it will be able to
establish in the bladder in an adhesion-independent manner.
Indeed, a theoretical analysis of bacterial growth in the bladder
suggested that many urinary tract isolates of E. coli had growth
rates that were fully compatible with nonadhesive establish-
ment in the bladder (11). So far, no studies have been pub-
lished that show that a high growth rate of a UPEC strain can
permit colonization of the urinary tract independent of specific
adhesion. Recently, Jarboe et al. predicted that pap expression
was inversely related to growth rate, indicating that at high
growth rates adherence may be unnecessary for persistence,
and so a decrease in fimbrial expression at high growth rates
potentially conserves cellular resources without decreasing the
probability of survival (18). A study on the UPEC isolate NU14
revealed that antibiotic resistance mutations led to significant
reduction of biological fitness (defined as decrease in growth
rate), providing a possible explanation for the observed nega-
tive correlation between fluoroquinolone resistance and bac-
terial virulence; the study revealed that the loss of fitness could
be partially reversed by later mutations (26).
E. coli strain 83972 was recently demonstrated to be unable
to express functional versions of type 1 and P fimbriae, the two
fimbriae types that are recognized as being the primary ad-
hesins of UTI E. coli strains (19). Furthermore, the strain has
never been reported to adhere to any kind of cells originating
from the human urinary tract (1, 15, 47). The lack of adhesion
could to a large degree account for the inability to cause
symptoms in the human host. However, it raises the issue of
how the strain is capable of staying in the bladder and how it
seems to be able to prevent bladder colonization by pathogenic
E. coli. The results presented herein indicate that strain 83972
grows very well in human urine in vitro, with doubling times
generally being 45 to 60 min. In some experiments, even
shorter doubling times were observed. Indeed, a comparison of
the doubling time of the 83972 strain with those of a spectrum
of well-characterized UPEC strains showed that it grows faster
than any of them. Also, it grows to higher maximum cell den-
sities and exhibits a shorter lag phase than any of the UPEC
strains investigated. This enhanced growth capacity in urine
was not a unique property of 83972, since other ABU isolates
from our laboratory strain collection exhibited similar growth
characteristics (data not shown).
When E. coli 83972 was pitted against the UPEC strains in
pairwise competition experiments, it outcompeted all of them
to a significant degree, i.e., the ABU strain constituted 71 to
97% of the population after overnight growth. Mathematical
modeling of the competition experiments, using the observed
doubling times (Fig. 1) and assuming exponential growth, re-
sulted in numbers closely resembling the values obtained ex-
perimentally (Fig. 2). These results were confirmed in mouse
experiments; the 83972 strain was almost totally dominant in
the urine of mice 24 h after receiving a mixed challenge con-
sisting of 83972 and the UPEC isolate NU14 (1:1). E. coli
83972 can establish long-term bacteriuria in humans (1, 14, 47,
49) and has been used extensively for treatment of patients
with recurrent UTI to avoid the establishment of disease-caus-
ing strains (8, 14, 44, 45, 49). Based on the results presented
here, we suggest that the ability of E. coli 83972 to establish in
the human bladder as well as its prophylactic properties against
UPEC strains is first and foremost due to its excellent growth
properties in human urine. In theory, strain 83972 could also
compete with other strains by killing them. However, we have
tested the strain for colicin production and it proved negative
in this faculty.
According to the literature, E. coli 83972 had grown in the
bladder of a girl with ABU for at least 3 years (1). This rep-
resents a substantial number of generations, i.e., more than
30,000, assuming generation times comparable to those ob-
served in the present study. During this period of time the
strain must have adapted considerably to this particular envi-
ronmental niche. The strain lost the ability to express func-
tional type 1 and P fimbriae probably as an evolutionary trade-
off with the host defense. This ensured that it did not attract
the attention of aggressive host defense mechanisms, such as
cytokine production, inflammation, and exfoliation of infected
bladder cells. However, in order to avoid being flushed out of
the system, it had to adapt to the growth medium, i.e., human
urine, and to optimize its growth rate to keep pace with the
flow rate in the bladder. Whether this happened during the
three-plus years it was carried by the particular girl or before
then in other hosts is not possible to conclude. It is, however,
interesting that the girl suffered from a voiding problem and
was unable to empty her bladder completely, thus leaving a
considerable volume of residual urine (1, 25). Arguably, this
would provide the 83972 strain with an ideal “training” envi-
ronment for optimizing its ability to grow in urine.
In a previous study on bacterial growth adaptation to a
specific growth medium, it was shown that after 10,000 gener-
ations E. coli strains had increased in fitness by 50% for
growth on glucose medium (22). In line with this notion, strain
83972 must have accrued genetic changes that have favored its
fitness for growth in urine. Human urine is a very complex
growth medium, and the composition of urine fluctuates daily
and varies with the person and diet. It is, however, known that
iron availability is a limiting factor. Our array data indicated
that strain 83972 has adapted well to growth in this iron-
limiting environment, significantly increasing the expression of
the majority of all known genes involved in iron uptake and
transport when grown in urine compared with minimal me-
dium. Furthermore, the array data revealed high expression
levels of genes involved in transportation and degradation
pathways of sugar acids and carbohydrates, indicating how E.
coli 83972 is able to reach high growth rates in human urine by
efficiently utilizing the nutrients available in this growth me-
dium. It should be noted, however, that even though the E. coli
arrays employed in this study include transcripts from the uro-
pathogenic strain CFT073, the whole genome of E. coli 83972
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has not yet been sequenced and characterized and, therefore,
the possibility that strain 83972 carries unique genes enabling
a faster growth in urine cannot be ruled out. It remains to be
seen whether the mechanisms utilized by E. coli 83972 are
superior to those of UPEC strains or whether this strain has
evolved additional, yet-undescribed mechanisms for iron se-
questration and growth. We are currently examining these
possibilities further.
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